5IU Stock Chart & Stats
€0.05
€0.01(5.26%)
At close: 4:00 PM EST
€0.05
€0.01(5.26%)
Day’s Range― - ―
52-Week Range€0.04 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€20.37M
Enterprise Value€71.98
Total Cash (Recent Filing)€110.74M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding320,491,640
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Lead AssetHaving a proprietary, clinical‑stage asset (arfolitixorin) focused on combinations with broadly used 5‑FU chemo is a durable strategic strength. It supports potential licensing, partnerships, or future commercial revenue if trials and approvals progress, underpinning long‑term value creation.
Very Low LeverageA zero debt profile materially reduces financial risk for a clinical‑stage biotech that lacks product revenue. Low leverage extends optionality for funding R&D, lowers solvency pressure during trial cycles, and preserves flexibility for partnering or staged financing over months to years.
Reduced Free Cash Outflow (TTM)The much smaller TTM free cash outflow signals operational improvement or timing of expenditures and materially lowers near‑term financing urgency. For a cash‑burn biotech, a narrower outflow improves runway management and reduces the frequency/size of dilutive capital raises.
Bears Say
No Revenue BaseZero revenue is a structural weakness: without a commercial product the firm must rely on financing or partnerships to fund development. This absence of recurring sales creates long lead times to profitability and sustained reliance on external capital, raising execution risk long term.
Large Operating Cash BurnA persistent, large negative operating cash flow (~-55.6M TTM) indicates substantial ongoing funding needs. Sustained high burn increases probability of dilutive financing, can constrain strategic choices, and pressures the company to secure partners or capital before key clinical inflection points.
Eroding Shareholder EquityMaterial decline in equity over several years reflects cumulative losses and likely dilution. This erosion reduces the balance sheet buffer to absorb setbacks, signals repeated capital raises, and weakens financial resilience to execute long, expensive clinical programs without adverse shareholder impacts.
Isofol Medical AB News
5IU FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was €0.04 and its highest was €0.09 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is €20.37M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Aug 25, 2026 which is in 28 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on May 19, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -€0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in DE:5IU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―